Highlights and Quick Summary
- Net Income for the quarter ending June 30, 2023 was $-11.2 Million (a -6.72% decrease compared to previous quarter)
- Year-over-year quarterly Net Income increased by 352.49%
- Annual Net Income for 2022 was $-35.3 Million (a -2.57% decrease from previous year)
- Annual Net Income for 2021 was $-36.3 Million (a 6131.1% increase from previous year)
- Annual Net Income for 2020 was $-582 Thousand (a -97.17% decrease from previous year)
- Twelve month Net Income ending June 30, 2023 was $-36.1 Million (a -1.01% decrease compared to previous quarter)
- Twelve month trailing Net Income increased by 13.29% year-over-year
Trailing Net Income for the last four month:
30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
---|---|---|---|
$-36.1 Million | $-36.5 Million | $-35.3 Million | $-31.9 Million |
Visit stockrow.com/DRRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Income of DURECT Corporation
Most recent Net Incomeof DRRX including historical data for past 10 years.Interactive Chart of Net Income of DURECT Corporation
DURECT Corporation Net Income for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2023 | $-11.18 | $-11.99 | – | – | – |
2022 | $-10.47 | $-2.47 | $-11.55 | $-10.84 | $-35.33 |
2021 | $-7.01 | $-9.98 | $-9.15 | $-10.13 | $-36.27 |
2020 | $4.36 | $-9.33 | $14.34 | $-9.95 | $-0.58 |
2019 | $-4.23 | $-1.99 | $-7.23 | $-7.13 | $-20.58 |
2018 | $-7.3 | $-2.72 | $-7.01 | $-8.3 | $-25.32 |
2017 | $8.24 | $6.11 | $-9.93 | $-8.11 | $-3.7 |
2016 | $-8.81 | $-8.83 | $-9.01 | $-7.85 | $-34.51 |
2015 | $-5.85 | $-6.49 | $-5.48 | $-4.85 | $-22.66 |
2014 | $-5.94 | $-7.09 | $-5.48 | $-3.6 | $-22.11 |
2013 | $-5.1 | $-6.02 | $-5.15 | $-5.18 | $-21.45 |
2012 | $-5.5 | $-4.8 | – | – | $16.2 |
Business Profile of DURECT Corporation
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic